Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03859050

Alveolar Macrophage Programming Following Endotoxin Exposure

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
National Jewish Health · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Conditions

Interventions

TypeNameDescription
OTHERbronchoscopy with intrabronchial administration of lipopolysaccharideThe PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.

Timeline

Start date
2019-03-18
Primary completion
2029-07-01
Completion
2032-07-01
First posted
2019-03-01
Last updated
2025-05-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03859050. Inclusion in this directory is not an endorsement.